A federal appeals court ruled against Amgen in the in re Kubin case. In 2000, the US Patent and Trademarks office rejected a patent application submitted by Immunex for the gene encoding the NAIL protein, which plays a role in immune response, because isolating the gene took "routine skill." Amgen, which bought Immunex in the interim, appealed the decision.